Merck Gets FDA Priority Review of Keytruda in Head, Neck Cancer

Date : 02/11/2019 @ 12:32PM
Source : Dow Jones News
Stock : Merck & Company (New) (MRK)
Quote : 84.49  1.19 (1.43%) @ 9:30PM

Merck Gets FDA Priority Review of Keytruda in Head, Neck Cancer

Merck (NYSE:MRK)
Historical Stock Chart

6 Months : From Dec 2018 to Jun 2019

Click Here for more Merck Charts.
   By Colin Kellaher 

Merck & Co. (MRK) on Monday said the U.S. Food and Drug Administration accepted and granted priority review for a supplemental biologics license application for the cancer drug Keytruda in head and neck cancer.

The Kenilworth, N.J., drug maker said the sBLA seeks approval for Keytruda as monotherapy or in combination with chemotherapy for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

Merck said the sBLA filing is partly based on data from a phase 3 study in which Keytruda showed a significant improvement in overall survival compared with the standard of care.

The FDA set a target action date of June 10, Merck said.

Keytruda, a cancer drug that harnesses a patient's immune systems to fight tumors, is already marketed to treat lung, skin, bladder and other cancers.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 11, 2019 07:17 ET (12:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.